Hydroxyzine as a Non-Habit-Forming Benzodiazepine Alternative
An 81-year-old who has already failed an SSRI and explicitly refuses dependence risk seems to want exactly what hydroxyzine offers. The real tradeoff is a different risk profile, not a risk-free one, at an age where anticholinergic burden matters just as much as fall risk.
Dorothy M., an 81-year-old widow, has generalized anxiety disorder and lives independently in an assisted-living apartment, managing her own medications with occasional help from her daughter. Her physician is reluctant to start a benzodiazepine given her age and the same fall/cognitive risk profile that would apply to any patient in her demographic, and an SSRI trial six months ago was discontinued after two weeks for significant nausea she found intolerable. She is asking for "something that works quickly" and specifically says she does not want anything that could become a habit, having watched a close friend struggle with a difficult benzodiazepine taper in her own final years.
Hydroxyzine, a first-generation antihistamine with genuine anxiolytic efficacy and no dependence or withdrawal profile, is a reasonable fit for exactly her stated priorities — but it carries its own real anticholinergic burden, a category of particular concern in older adults for sedation, falls, constipation, urinary retention, and potential cognitive effects with regular use, especially layered onto any other anticholinergic-active medications she might already be taking. The tradeoff isn't dependence-risk-free versus dependence-risk-present; it's one real risk profile against a different real risk profile, both relevant at her age.
Her daughter, who joined by phone for part of the visit, confirms Dorothy has been managing her own weekly pill organizer without error for years and has no history of falls to date — useful baseline information the team notes explicitly, since it means any new fall or confusion after starting a new medication would be a meaningful change worth catching quickly, not background noise.
Weighing anticholinergic burden against dependence risk
Hydroxyzine genuinely answers her stated priority of avoiding dependence, but it's not a risk-free substitute — its anticholinergic burden is a real concern at her age, independently associated with falls, constipation, and potential cognitive effects, especially with regular rather than occasional use. This needs to be presented to her as a different real tradeoff, not a clean answer to the benzodiazepine concern. Worth naming the symmetry outright: the Beers Criteria she'd be avoiding a benzodiazepine over also flag first-generation antihistamines like hydroxyzine in adults her age, and for overlapping reasons. Neither option is off that list.
Her current medication list has no other anticholinergic-active agents, which meaningfully reduces the cumulative-burden concern compared to a patient already on several such drugs — the anticholinergic risk here is real but starts from a genuinely lower baseline than it would in a more polypharmacy-heavy patient her age.
Given her SSRI intolerance and clearly stated priorities, a low-dose hydroxyzine trial, used primarily as needed rather than fixed-schedule daily dosing to limit cumulative anticholinergic exposure, is a reasonable next step — with fall risk and any emerging constipation or cognitive change checked specifically at her next visit rather than assumed absent.
Agreed: hydroxyzine started at a low dose, used primarily as needed rather than on a fixed schedule, with fall risk, constipation, and cognitive status explicitly checked at her next visit rather than assumed unaffected.